Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2023

Genmab — Juli 2023

Planlagt Fastgjort Låst Flyttet Genmab
551 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    peter12
    wrote on sidst redigeret af
    #114

    Man kan diskutere om det er etisk korrekt at lave sådan et forsøg ?

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #115

      Wat do you mean Peter? The fact that the stage IIIb patients were excluded from the first trial?

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #116

        https://www.prnewswire.com/news-releases/treatment-with-rybrevant-amivantamab-vmjw-plus-chemotherapy-resulted-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-egfr-exon-20-insertion-mutati-301878443.html?tc=eml_cleartime Treatment with RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with Newly Diagnose

        1 Reply Last reply
        0
        • A Offline
          A Offline
          AaBforever
          wrote on sidst redigeret af
          #117

          Nå...nu ser det da ud til at retningen er UP:-)

          1 Reply Last reply
          0
          • D Offline
            D Offline
            deleted-user
            wrote on sidst redigeret af
            #118

            Ja og snakken om kurs 2450 forstummede. Saxo kører med et muligt bull signal omkring 2950 over 50 dage, hvis wedgen bryde op

            1 Reply Last reply
            0
            • T Offline
              T Offline
              Teller
              wrote on sidst redigeret af
              #119

              Bliver spændende om stigningen kan modnes hen over ugen 🙂

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #120

                Vi kan jo håbe på gode salgstal på torsdag.

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  Pensionisten
                  wrote on sidst redigeret af
                  #121

                  Genmab (+2,3%, 2686) parternen Novartis øgede i andet kvartal salget af Kesimpta til 489 mio. dollar. Det svarer til en stigning på 105 pct. sammenlignet med salget i samme kvartal sidste år. Kesimpta til behandling af multipel sklerose er baseret på Genmabs virkemiddel Ofatumumab, og Genmab modtager 10 pct. af salget i royalties. Kilde: Landbobanken Børsnyt

                  1 Reply Last reply
                  0
                  • P Offline
                    P Offline
                    ProinvestorNEWS
                    wrote on sidst redigeret af
                    #122

                    Schweizisk Genmab-partner opjusterer efter overbevisende kvartal https://www.proinvestor.com/investornyt/1016615/schweizisk-genmab-partner-opjusterer-efter-overbevisende-kvartal

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #123

                      Mon ikke vi kan nærme os en dobbelt BB i år for Kesimpta - ikke dårligt

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #124

                        Novartis Q2 2023 Results
                        Investor
                        presentation https://www.novartis.com/sites/novartis_com/files/q2-2023-investor-presentation.pdf

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #125

                          Q1: $386 mln, Q2: $489 mln og $873 mln for H123. Vi er vel over BB nu 🙂 https://www.novartis.com/sites/novartis_com/files/q2-2023-media-release-en.pdf side 5

                          1 Reply Last reply
                          0
                          • nohopeN Offline
                            nohopeN Offline
                            nohope
                            wrote on sidst redigeret af
                            #126

                            h

                            1 Reply Last reply
                            0
                            • nohopeN Offline
                              nohopeN Offline
                              nohope
                              wrote on sidst redigeret af
                              #127

                              Han bad om dobbelt BB = 2 MIA

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #128

                                Ok det bliver det også 🙂

                                1 Reply Last reply
                                0
                                • SolsenS Offline
                                  SolsenS Offline
                                  Solsen
                                  wrote on sidst redigeret af
                                  #129

                                  Imponerende tempo Novartis har på udrulningen. Mange nye pts på Kesimpta.

                                  1 Reply Last reply
                                  0
                                  • J Offline
                                    J Offline
                                    JKY_VH
                                    wrote on sidst redigeret af
                                    #130

                                    Jep, som at se Vinge på enkeltstarten 😉

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #131

                                      Hvem sagde “kannibalen”?

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        JKY_VH
                                        wrote on sidst redigeret af
                                        #132

                                        hehe Bulder;-)

                                        1 Reply Last reply
                                        0
                                        • P Offline
                                          P Offline
                                          ProinvestorNEWS
                                          wrote on sidst redigeret af
                                          #133

                                          Novartis Ag (NVS) Q2 2023 Earnings Call Transcript https://www.proinvestor.com/investornyt/1017067/novartis-ag-nvs-q2-2023-earnings-call-transcript

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper